These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 24070205

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Molecular basis for sunitinib efficacy and future clinical development.
    Faivre S, Demetri G, Sargent W, Raymond E.
    Nat Rev Drug Discov; 2007 Sep; 6(9):734-45. PubMed ID: 17690708
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R.
    Clin Cancer Res; 2007 Mar 01; 13(5):1367-73. PubMed ID: 17332278
    [Abstract] [Full Text] [Related]

  • 5. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
    Motzer RJ, Escudier B, Gannon A, Figlin RA.
    Oncologist; 2017 Jan 01; 22(1):41-52. PubMed ID: 27807302
    [Abstract] [Full Text] [Related]

  • 6. Sunitinib: from rational design to clinical efficacy.
    Chow LQ, Eckhardt SG.
    J Clin Oncol; 2007 Mar 01; 25(7):884-96. PubMed ID: 17327610
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib for advanced pancreatic neuroendocrine tumors.
    Hubner RA, Valle JW.
    Expert Rev Anticancer Ther; 2011 Dec 01; 11(12):1817-27. PubMed ID: 22117148
    [Abstract] [Full Text] [Related]

  • 8. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 01; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL.
    J Oncol Pharm Pract; 2007 Mar 01; 13(1):5-15. PubMed ID: 17621562
    [Abstract] [Full Text] [Related]

  • 11. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
    Cabebe E, Wakelee H.
    Drugs Today (Barc); 2006 Jun 01; 42(6):387-98. PubMed ID: 16845442
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R.
    Oncologist; 2007 Jan 01; 12(1):107-13. PubMed ID: 17227905
    [Abstract] [Full Text] [Related]

  • 15. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
    Sablin MP, Dreyer C, Colichi C, Bouattour M, Delbaldo C, Faivre S, Raymond E.
    Expert Opin Drug Metab Toxicol; 2010 Aug 01; 6(8):1005-15. PubMed ID: 20636223
    [Abstract] [Full Text] [Related]

  • 16. Sunitinib for the treatment of thyroid cancer.
    Gómez-Sáez JM.
    Expert Opin Investig Drugs; 2016 Nov 01; 25(11):1345-1352. PubMed ID: 27677828
    [Abstract] [Full Text] [Related]

  • 17. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
    George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD.
    Eur J Cancer; 2009 Jul 01; 45(11):1959-68. PubMed ID: 19282169
    [Abstract] [Full Text] [Related]

  • 18. Sunitinib malate.
    Izzedine H, Buhaescu I, Rixe O, Deray G.
    Cancer Chemother Pharmacol; 2007 Aug 01; 60(3):357-64. PubMed ID: 17136543
    [Abstract] [Full Text] [Related]

  • 19. Sunitinib malate in the treatment of urothelial cancer.
    Pons F, Bellmunt J.
    Expert Opin Investig Drugs; 2014 Jan 01; 23(1):115-24. PubMed ID: 24188025
    [Abstract] [Full Text] [Related]

  • 20. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.
    JAMA; 2006 Jun 07; 295(21):2516-24. PubMed ID: 16757724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.